Board of Directors

Mr. Angotti brings over two decades of experience leading executive and commercial teams at public and private life sciences companies, most recently as CEO of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for neuropathic pain and other neurological disorders. During his tenure at XenoPort, Mr. Angotti was involved in the re-acquisition of Horizant from GSK and implemented a successful re-branding and re-launch strategy leading to XenoPort's acquisition by Arbor Pharmaceuticals, LLC in 2016. Previous to joining XenoPort, Mr. Angotti held senior sales and marketing positions at Reliant Pharmaceuticals, Inc. from 2001 – 2008. In his role as senior vice president of sales and marketing at Reliant, Mr. Angotti was integrally involved in the company's M&A discussions that concluded with Reliant's acquisition by GSK in 2007. Mr. Angotti began his career in the life sciences industry at Novartis Pharmaceuticals Corp., where he worked from 1991 – 2001 in sales and operations positions of increasing responsibility. Mr. Angotti earned a Bachelor of Science with a concentration in business management from Cornell University in 1990 and a Master of Business Administration with honors in 2000 from Columbia University.

Ms. Broadfoot currently serves as the chief financial officer of aTyr Pharma, Inc., a position she has held since July 2018. From January 2017 to July 2018, Ms. Broadfoot served as chief financial officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceutical entities as well as the establishment of operations, corporate governance, finance and accounting and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as vice president, U.S. corporate controller at GW Pharmaceuticals, from May 2016 to January 2017. While at GW Pharmaceuticals, her responsibilities included establishing U.S. commercial operations and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as chief financial officer of Vical Inc., from October 2004 to March 2013, where she had oversight of finance, investor relations, manufacturing, information technology, human resources, and business development. Ms. Broadfoot holds a Bachelor of Science in business administration and accounting from San Diego State University and is a certified public accountant.

Ms. Bozilenko has served as our director since March 2021. Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions. Since June 2021, Ms. Bozilenko has served as president, chief executive officer and a member of the board of directors at Biothea Pharma, Inc. and since February 2021, she has served as a strategic advisor to William Blair & Company, a firm she joined in 2010 as head of biotech & pharma and managing director. Prior to that, she worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group, at Bank of America Securities as a managing director and head of biotechnology, and at Vector Securities International, where she was a partner. Ms. Bozilenko was also a principal at Kidd & Company, a private-equity firm. She received her Bachelor of Arts in molecular biology and Master of Arts in economic history from the University of Chicago.

Dr. Hoffman has served as a director on the AcelRx board since February 2010. Dr. Hoffman served as chief executive officer and director of Aerpio Pharmaceuticals, Inc., from December 2017 to October 2019. Prior to that, Dr. Hoffman had been a senior advisor to PDL BioPharma, Inc. beginning in February 2014. Prior to that, he served as a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February 2014. From January 2003 to March 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm. From 1994 to 2012, Dr. Hoffman served as president, chief executive officer and a director of Allos Therapeutics, a biopharmaceutical company; and served as chairman of the board of directors from 2002 until its acquisition by Spectrum Pharmaceuticals in 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired in 1998 by Baxter International, Inc., a global medical products and services company, where he held the position of vice president of science and technology from 1987 until 1990.Dr. Hoffman currently serves on the board of directors of BYOMass Therapeutics, Inc., and Implicit Bioscience, Ltd. Dr. Hoffman holds a doctorate in bio-organic chemistry from Northwestern University and a medical degree from the University of Colorado School of Medicine.

Abhinav “Abi” Jain has served as a director on the Talphera Board of Directors since 2024. He is an Analyst at Nantahala Capital Management and is focused on investments in various sectors, including specialty and generic pharmaceuticals. Prior to joining Nantahala in 2019, Mr. Jain was an Associate at Angelo, Gordon & Co., an alternative asset manager based in New York from 2015-2017. At Angelo, Gordon & Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.

Mr. Wan has served as a director on the AcelRx board since August 2006. Mr. Wan is a founding managing director of Causeway Media Partners. Prior to Causeway, he was a founding general partner of Three Arch Partners, a venture capital firm. Prior to co-founding Three Arch Partners in 1993, Mr. Wan was a general partner at Brentwood Associates, a private equity firm. Mr. Wan holds a Bachelor of Science in engineering and a Bachelor of Arts in economics from Yale University and a Master of Business Administration from the Stanford Graduate School of Business.